John L Johnson, M.D., FACP
Associate Professor of Medicine and International Health
Staff Physician, University Hospitals of Cleveland
Education
MD - University of Pittsburgh, 1981
Special Training
Pulmonary/Critical Care Medicine – Case Western Reserve
University/University Hospitals of Cleveland, 1987
Office 216-844-2646
Email john.johnson@case.edu
Research Area
Tuberculosis, HIV/AIDS
Research
Dr. Johnson’s major research focus is phase I, II, and
III IND and non-IND clinical trials of new drugs, immunotherapeutic
agents and vaccines for the prevention and treatment of tuberculosis.
Other areas of interest include HIV and TB interactions, immunopathogenesis
of tuberculosis and M. avium complex disease, TB diagnostics,
surrogate markers of response to TB treatment, pulmonary infections
in immunocompromised persons, HIV vaccines and research capacity
strengthening in developing countries. Dr. Johnson is the component
leader for clinical trials for the NIH-sponsored Tuberculosis
Research Unit at CWRU and the Principal Investigator for TB
clinical trials for Site 30 - Kampala, Uganda of the CDC-sponsored
Tuberculosis Trials Consortium (TBTC) network. Dr. Johnson works
closely with international collaborators in Uganda, Brazil and
the Philippines.
Selected Publications
• Johnson JL, Ssekasanvu E, Okwera A, Mayanja H, Hirsch
CS, Nakibali J, Drzayich Jankus D, Eisenach KD, Boom WH, Ellner
JJ, Mugerwa RD for the Uganda-Case Western Reserve University
Research Collaboration.
Randomized trial of adjunctive interleukin-2 in adults with
pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168:185-191.
• Wallis RS, Vinhas SA, Johnson JL, Ribeiro FC, Palaci
M, Peres RL, Sá RT, Dietze R, Chiunda A, Eisenach K,
Ellner JJ.
Whole blood bactericidal activity during treatment of pulmonary
tuberculosis. J Infect Dis 2003;187:270-278.
• Ribeiro-Rodrigues R, Co TR, Johnson JL, Ribeiro F,
Palaci M, Sá RT, Maciel EL, Lima FEP, Dettoni V, Toossi
Z, Boom WH, Dietze R, Ellner JJ, Hirsch CS.
Sputum cytokine levels in patients with pulmonary tuberculosis
as early markers of mycobacterial clearance. Clin Diagn Lab
Immunol 2002;9: 818-823.
• Johnson JL, Okwera A. Hom DL, Mayanja H, Kityo C, Nsubuga
P, Nakibali JG, Loughlin AM, Mugyenyi PN, Vernon A, Mugerwa
RD, Ellner JJ, Whalen CC for the Uganda-Case Western Reserve
University Research Collaboration.
Duration of efficacy of treatment of latent tuberculosis infection
in HIV-infected adults. AIDS 2001;15 (16):2137-2147.
